- Home
- ACXP vs CLDI Comparison
ACXP vs CLDI Comparison
Compare ACXP & CLDI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACXP
- CLDI
- Stock Information
- Founded
- ACXP 2017
- CLDI 2014
- Country
- ACXP United States
- CLDI United States
- Employees
- ACXP N/A
- CLDI N/A
- Industry
- ACXP Biotechnology: Pharmaceutical Preparations
- CLDI Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- ACXP Health Care
- CLDI Health Care
- Exchange
- ACXP Nasdaq
- CLDI Nasdaq
- Market Cap
- ACXP 31.4M
- CLDI 35.2M
- IPO Year
- ACXP 2021
- CLDI N/A
- Fundamental
- Price
- ACXP $0.78
- CLDI $1.05
- Analyst Decision
- ACXP Strong Buy
- CLDI Strong Buy
- Analyst Count
- ACXP 1
- CLDI 3
- Target Price
- ACXP $12.00
- CLDI $16.67
- AVG Volume (30 Days)
- ACXP 132.1K
- CLDI 2.7M
- Earning Date
- ACXP 03-14-2025
- CLDI 03-14-2025
- Dividend Yield
- ACXP N/A
- CLDI N/A
- EPS Growth
- ACXP N/A
- CLDI N/A
- EPS
- ACXP N/A
- CLDI N/A
- Revenue
- ACXP N/A
- CLDI N/A
- Revenue This Year
- ACXP N/A
- CLDI N/A
- Revenue Next Year
- ACXP N/A
- CLDI N/A
- P/E Ratio
- ACXP N/A
- CLDI N/A
- Revenue Growth
- ACXP N/A
- CLDI N/A
- 52 Week Low
- ACXP $0.67
- CLDI $0.58
- 52 Week High
- ACXP $3.35
- CLDI $16.80
- Technical
- Relative Strength Index (RSI)
- ACXP 49.91
- CLDI 45.04
- Support Level
- ACXP $0.67
- CLDI $1.16
- Resistance Level
- ACXP $0.76
- CLDI $1.30
- Average True Range (ATR)
- ACXP 0.04
- CLDI 0.24
- MACD
- ACXP 0.00
- CLDI 0.01
- Stochastic Oscillator
- ACXP 75.28
- CLDI 40.10
About ACXP Acurx Pharmaceuticals Inc.
Acurx Pharmaceuticals Inc is a clinical stage biopharmaceutical company developing a new class of antibiotics for infections caused by bacteria listed as priority pathogens by the World Health Organization, Centers for Disease Control and Prevention and Food and Drug Administration.
About CLDI Calidi Biotherapeutics Inc.
Calidi Biotherapeutics Inc is a clinical stage immuno-oncology company pioneering the development and commercialization of novel, potent and efficient stem cell-based platforms for delivery and potentiation of oncolytic viruses for the treatment of cancer.